annual cash & cash equivalents:
$1.08B+$461.19M(+74.97%)Summary
- As of today (September 14, 2025), CYTK annual cash & cash equivalents is $1.08 billion, with the most recent change of +$461.19 million (+74.97%) on December 31, 2024.
- During the last 3 years, CYTK annual cash & cash equivalents has risen by +$604.75 million (+128.22%).
- CYTK annual cash & cash equivalents is now at all-time high.
Performance
CYTK Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$859.75M-$78.85M(-8.40%)Summary
- As of today (September 14, 2025), CYTK quarterly cash & cash equivalents is $859.75 million, with the most recent change of -$78.85 million (-8.40%) on June 30, 2025.
- Over the past year, CYTK quarterly cash & cash equivalents has dropped by -$197.40 million (-18.67%).
- CYTK quarterly cash & cash equivalents is now -20.13% below its all-time high of $1.08 billion, reached on December 31, 2024.
Performance
CYTK quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CYTK Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +75.0% | -18.7% |
| 3 y3 years | +128.2% | +46.7% |
| 5 y5 years | +378.2% | +303.5% |
CYTK Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +128.2% | -20.1% | +59.3% |
| 5 y | 5-year | at high | +378.2% | -20.1% | +303.5% |
| alltime | all time | at high | +2095.7% | -20.1% | +7722.3% |
CYTK Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $859.75M(-8.4%) |
| Mar 2025 | - | $938.59M(-12.8%) |
| Dec 2024 | $1.08B(+75.0%) | $1.08B(+6.4%) |
| Sep 2024 | - | $1.01B(-4.3%) |
| Jun 2024 | - | $1.06B(+70.7%) |
| Mar 2024 | - | $619.34M(+0.7%) |
| Dec 2023 | $615.20M(-21.4%) | $615.20M(+14.0%) |
| Sep 2023 | - | $539.61M(-4.7%) |
| Jun 2023 | - | $566.10M(-14.9%) |
| Mar 2023 | - | $665.56M(-15.0%) |
| Dec 2022 | $782.58M(+65.9%) | $782.58M(-9.8%) |
| Sep 2022 | - | $867.66M(+48.1%) |
| Jun 2022 | - | $586.03M(-3.8%) |
| Mar 2022 | - | $608.97M(+29.1%) |
| Dec 2021 | $471.64M(+1.6%) | $471.64M(-1.3%) |
| Sep 2021 | - | $477.64M(+36.4%) |
| Jun 2021 | - | $350.30M(-17.7%) |
| Mar 2021 | - | $425.58M(-8.3%) |
| Dec 2020 | $464.06M(+106.1%) | $464.06M(+13.1%) |
| Sep 2020 | - | $410.26M(+92.6%) |
| Jun 2020 | - | $213.06M(-3.5%) |
| Mar 2020 | - | $220.71M(-2.0%) |
| Dec 2019 | $225.11M(+13.3%) | $225.11M(+35.6%) |
| Sep 2019 | - | $166.04M(-4.0%) |
| Jun 2019 | - | $172.87M(-2.1%) |
| Mar 2019 | - | $176.62M(-11.1%) |
| Dec 2018 | $198.73M(-26.1%) | $198.73M(-5.5%) |
| Sep 2018 | - | $210.31M(-9.3%) |
| Jun 2018 | - | $231.94M(-7.8%) |
| Mar 2018 | - | $251.45M(-6.5%) |
| Dec 2017 | $268.89M(+72.1%) | $268.89M(-12.6%) |
| Sep 2017 | - | $307.57M(-1.4%) |
| Jun 2017 | - | $312.05M(+51.1%) |
| Mar 2017 | - | $206.56M(+32.2%) |
| Dec 2016 | $156.25M(+40.2%) | $156.25M(+98.8%) |
| Sep 2016 | - | $78.61M(-13.0%) |
| Jun 2016 | - | $90.34M(-12.7%) |
| Mar 2016 | - | $103.42M(-7.2%) |
| Dec 2015 | $111.44M(+33.9%) | $111.44M(+13.7%) |
| Sep 2015 | - | $97.98M(-6.8%) |
| Jun 2015 | - | $105.18M(-2.5%) |
| Mar 2015 | - | $107.87M(+29.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $83.23M(+7.1%) | $83.23M(+6.0%) |
| Sep 2014 | - | $78.50M(+1.0%) |
| Jun 2014 | - | $77.75M(-5.6%) |
| Mar 2014 | - | $82.35M(+5.9%) |
| Dec 2013 | $77.73M(+5.0%) | $77.73M(-4.8%) |
| Sep 2013 | - | $81.64M(+7.9%) |
| Jun 2013 | - | $75.65M(+22.8%) |
| Mar 2013 | - | $61.60M(-16.8%) |
| Dec 2012 | $74.00M(+50.9%) | $74.00M(-2.1%) |
| Sep 2012 | - | $75.61M(-16.4%) |
| Jun 2012 | - | $90.47M(+110.0%) |
| Mar 2012 | - | $43.08M(-12.1%) |
| Dec 2011 | $49.02M(-57.3%) | $49.02M(-14.9%) |
| Sep 2011 | - | $57.59M(-13.9%) |
| Jun 2011 | - | $66.91M(+11.7%) |
| Mar 2011 | - | $59.90M(-31.6%) |
| Jun 2010 | - | $87.58M(-23.7%) |
| Dec 2009 | $114.73M(+101.7%) | $114.73M(-5.6%) |
| Sep 2009 | - | $121.59M(-7.9%) |
| Jun 2009 | - | $131.98M(+105.9%) |
| Mar 2009 | - | $64.10M(+12.7%) |
| Dec 2008 | $56.87M(-52.5%) | $56.87M(-19.5%) |
| Sep 2008 | - | $70.64M(-18.7%) |
| Jun 2008 | - | $86.86M(-17.7%) |
| Mar 2008 | - | $105.54M(-11.9%) |
| Dec 2007 | $119.74M(+9.3%) | $119.74M(-21.7%) |
| Sep 2007 | - | $152.94M(-1.6%) |
| Jun 2007 | - | $155.47M(-8.3%) |
| Mar 2007 | - | $169.55M(+54.8%) |
| Dec 2006 | $109.54M(+43.7%) | $109.54M(+23.5%) |
| Sep 2006 | - | $88.69M(-6.6%) |
| Jun 2006 | - | $94.92M(-6.3%) |
| Mar 2006 | - | $101.26M(+32.9%) |
| Dec 2005 | $76.21M(-37.4%) | $76.21M(-5.4%) |
| Sep 2005 | - | $80.56M(-9.6%) |
| Jun 2005 | - | $89.10M(-12.3%) |
| Mar 2005 | - | $101.63M(-15.3%) |
| Jun 2004 | - | $119.92M(+330.5%) |
| Mar 2004 | - | $27.86M(+153.5%) |
| Dec 2003 | $121.72M(+109.3%) | $10.99M |
| Dec 2001 | $58.17M(+2.4%) | - |
| Dec 2000 | $56.79M | - |
FAQ
- What is Cytokinetics, Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cytokinetics, Incorporated?
- What is Cytokinetics, Incorporated annual cash & cash equivalents year-on-year change?
- What is Cytokinetics, Incorporated quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Cytokinetics, Incorporated?
- What is Cytokinetics, Incorporated quarterly cash & cash equivalents year-on-year change?
What is Cytokinetics, Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of CYTK is $1.08B
What is the all time high annual cash & cash equivalents for Cytokinetics, Incorporated?
Cytokinetics, Incorporated all-time high annual cash & cash equivalents is $1.08B
What is Cytokinetics, Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, CYTK annual cash & cash equivalents has changed by +$461.19M (+74.97%)
What is Cytokinetics, Incorporated quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CYTK is $859.75M
What is the all time high quarterly cash & cash equivalents for Cytokinetics, Incorporated?
Cytokinetics, Incorporated all-time high quarterly cash & cash equivalents is $1.08B
What is Cytokinetics, Incorporated quarterly cash & cash equivalents year-on-year change?
Over the past year, CYTK quarterly cash & cash equivalents has changed by -$197.40M (-18.67%)